Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells
Authors:
- Ioanna NikitopoulouINIoanna Nikitopoulou
- Dionysios FanidisDFDionysios Fanidis
- Konstantinos NtatsoulisKNKonstantinos Ntatsoulis
- Panagiotis MoulosPanagiotis Moulos
- George MpekoulisGMGeorge Mpekoulis
- Maria EvangelidouMEMaria Evangelidou
- Alice G. VassiliouAVAlice G. Vassiliou
- Vasiliki DimakopoulouVDVasiliki Dimakopoulou
- Edison JahajEJEdison Jahaj
- Stamatios TsipilisSTStamatios Tsipilis
- Stylianos E. OrfanosSOStylianos E. Orfanos
- Ioanna DimopoulouIDIoanna Dimopoulou
Open Access
- 16 September 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (18) , 10006
Abstract
Autotaxin (ATX; ENPP2) is a secreted lysophospholipase D catalyzing the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling phospholipid. Genetic and pharmacologic studies have previously established a pathologic role for ATX and LPA signaling in pulmonary injury, inflammation, and fibrosis. Here, increased ENPP2 mRNA levels were detected in immune cells from nasopharyngeal swab samples of COVID-19 patients, and increased ATX serum levels were found in severe COVID-19 patients. ATX serum levels correlated with the corresponding increased serum levels of IL-6 and endothelial damage biomarkers, suggesting an interplay of the ATX/LPA axis with hyperinflammation and the associated vascular dysfunction in COVID-19. Accordingly, dexamethasone (Dex) treatment of mechanically ventilated patients reduced ATX levels, as shown in two independent cohorts, indicating that the therapeutic benefits of Dex include the suppression of ATX. Moreover, large scale analysis of multiple single cell RNA sequencing datasets revealed the expression landscape of ENPP2 in COVID-19 and further suggested a role for ATX in the homeostasis of dendritic cells, which exhibit both numerical and functional deficits in COVID-19. Therefore, ATX has likely a multifunctional role in COVID-19 pathogenesis, suggesting that its pharmacological targeting might represent an additional therapeutic option, both during and after hospitalization.Keywords
All Related Versions
Funding Information
- General secreteriat of research and technology (T1EDK-0049)
This publication has 101 references indexed in Scilit:
- Lpa2 Is a Negative Regulator of Both Dendritic Cell Activation and Murine Models of Allergic Lung InflammationThe Journal of Immunology, 2012
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variationNucleic Acids Research, 2012
- Autotaxin Regulates Vascular Development via Multiple Lysophosphatidic Acid (LPA) Receptors in ZebrafishJournal of Biological Chemistry, 2011
- Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acidJournal of Lipid Research, 2011
- Differential expression analysis for sequence count dataGenome Biology, 2010
- Tmem176B and Tmem176A are associated with the immature state of dendritic cellsJournal of Leukocyte Biology, 2010
- ATX expression and LPA signalling are vital for the development of the nervous systemDevelopmental Biology, 2010
- Transcription Factor E2-2 Is an Essential and Specific Regulator of Plasmacytoid Dendritic Cell DevelopmentCell, 2008
- Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organsNature Immunology, 2008
- Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during DevelopmentMolecular and Cellular Biology, 2006